Stone House Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Stone House Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-90	Closed	-$3.06K	–	532
2025 Q1	$3.06K	Buy	+90	New	+$3.81K	﹤0.01%	359
2024 Q4	–	Sell	-460	Closed	-$21.6K	–	120
2024 Q3	$21.6K	Sell	460 -66	-13%	-$3.35K	﹤0.01%	174
2024 Q2	$28.4K	Sell	526 -43	-8%	-$2.49K	0.01%	161
2024 Q1	$38.8K	Buy	569 +400	+237%	+$28.6K	0.01%	145
2023 Q4	$10.6K	Sell	169 -27	-14%	-$1.49K	﹤0.01%	160
2023 Q3	$8.9K	Hold	196	–	–	﹤0.01%	169
2023 Q2	$11K	Hold	196	–	–	﹤0.01%	155
2023 Q1	$8.87K	Buy	+196	New	+$9.52K	﹤0.01%	171

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stone House Investment Management's CRSP Position: Q2 2025 in Review

Stone House Investment Management sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 90 shares — an estimated $3.06K sold.

Stone House Investment Management first reported a position in CRSP in Q1 2023 and held it in 8 quarters. The position peaked at $38.8K in Q1 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

Stone House Investment Management reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
Stone House Investment Management sold 90 CRISPR Therapeutics shares in Q2 2025, an estimated $3.06K.
Stone House Investment Management first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 8 quarters.
Stone House Investment Management's CRISPR Therapeutics position peaked at $38.8K in Q1 2024.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Stone House Investment Management's 13F filing for Q2 2025, filed 6 Aug 2025.